Category list : Pharmaceutical companies
Sort by: Newest first Oldest first A-Z Z-A
-
Revealed: the generic price hikes increasing the NHS drugs bill Subscription
Far from being a money saver, the generic medicines market has cost the NHS an additional £76m over the past two years.
-
Just out of reach: why the UK must rethink its barriers to novel medicines Subscription
The early access to medicines scheme has been running for six years, but has it had the desired impact of ensuring the sickest patients are spared the wait for the most promising treatments, or is it failing to live up to expectations?
-
We must learn the lessons from Priadel Subscription
The discontinuation of Priadel shows we need a tougher regulatory environment to prevent firms making commercial decisions that put vulnerable patients at risk.
-
NHS England boss accuses Priadel manufacturer of using COVID-19 to ‘price-gouge’ British taxpayers Subscription
The chief executive of NHS England has accused the manufacturer of a first-line medication for bipolar disorder of “trying to jack the prices of a long-standing medicine”.
-
Health bodies make ‘urgent’ call to Matt Hancock to intervene in the proposed withdrawal of bipolar drug Subscription
The health secretary, Matt Hancock, has been urged to “personally intervene” so that bipolar drug Priadel remains available in the UK with an appropriate pricing structure.
-
Manufacturers asked to retain Brexit medicine stockpiles amid supply concerns over coronavirus
The government has asked pharmaceutical companies to keep their no-deal Brexit medicine stockpiles as a precaution against shortages arising from the spread of the coronavirus in China.
-
Clinical pipeline of new antibiotics remains small, global report highlights Subscription
A quarter of clinical-stage antibiotics are supported by plans to ensure better access and good stewardship after launch compared to 7% in 2018, but the clinical pipeline of antibiotics for priority infections remains small, according to a report published by the Access to Medicine Foundation.
-
Assessing environmental impact of medicines financially 'catastrophic' for pharmaceutical industry Subscription
Assessing the environmental risks of a new medicine as part of the risk-benefit assessment during market authorisation would be “catastrophic” for the pharmaceutical industry, an environmental scientist from manufacturer AstraZeneca has said.
-
NHS trials new payment system to encourage development of new antibiotics Subscription
A subscription-style payment system is to be trialled by the NHS to help encourage the development of new antibiotics, the health secretary has announced.
-
Government cap on branded medicine prices may be unsustainable, warns ABPI Subscription
An ongoing cap on the price of branded medicines to the NHS “may not be sustainable” in the long term, the Association of the British Pharmaceutical Industry has said.
